Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tetragenetics has announced preclinical study results showing that the investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.
Subscribe to our email newsletter
The study was conducted under a contract sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Tetragenetics scientists produced a recombinant nanoparticle vaccine against a highly pathogenic avian influenza virus subtype, namely the H5N1 strain.
The study finds, at lethal doses of influenza, 90% in the treatment group that were immunized with the company’s vaccine survived the lethal challenge.
The vaccine candidate was comprised of the viral hemagglutinin linked to a protein from Tetrahymena thermophila that promotes assembly into homogenous nanoparticles in the 40-60nm size range (G-SOME particles).
Tetragenetics CSO and founder Ted Clark said the results demonstrate the use of Tetrahymena as a versatile expression system for the production of nanoscale particle-based vaccines against infectious disease agents.